Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

March 23, 2026

Roche to initiate Phase III study to expand access to ElevidysTM , the first approved gene therapy for Duchenne muscular dystrophy

April 21, 2026

PTC Therapeutics Provides Update to Duchenne Community Following Withdrawal of Ataluren Application

April 1, 2026

On March 31, 2026, PTC Therapeutics, Inc. provided an update to the Duchenne community following the withdrawal of the ataluren (Translarna) approval application in the United States.

To view their letter with updates, please click here.